Iovance Biotherapeutics to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference

SAN CARLOS, Calif., Nov. 28, 2017 -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that Dr. Maria Fardis, PhD, MBA, President and Chief Executive Officer, will participate in a fireside chat at the Evercore ISI Biopharma Catalyst/Deep Dive Conference on Thursday, November 30, 2017 at 11:00 a.m. ET in Boston, MA.

A live audio webcast of the presentation will be available by visiting the Investors section Iovance Biotherapeutics' website at http://ir.iovance.com/. A replay of the webcast will be archived on Iovance Biotherapeutics’ website for 30 days following the presentation.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck and recurrent and metastatic or persistent cervical cancer. For more information, please visit http://www.iovance.com.

Investor Relations Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
[email protected]

Media Relations Contact:
Evan Smith
FTI Consulting
212-850-5622
[email protected]